|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...1718192021222324252627...6566» |
- Clinical data, Enrollment open: Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=100, Recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Recruiting
- Enrollment open, Trial primary completion date: Quinolone Resistance in Bloodstream Isolates of Escherichia Coli (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=500, Recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- Trial completion: Community - Associated Extended-spectrum Beta-lactamases (ESBL) (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=100, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- Trial completion: Antibiotic Resistant Community-Acquired E. Coli (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=1000, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=300, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Active, not recruiting --> Completed
- colistin sulphate / Generic mfg.
Trial completion, Trial primary completion date: Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036) (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=10, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2015
- Trial primary completion date, Gram negative: Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=1000, Active, not recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial completion: AIMHi: Testing the Use of Prompts to Increase Adolescent Immunization Rates (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=7040, Completed, Sponsor: University of California, Los Angeles
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- ||||| Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
New P4 trial: Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier (clinicaltrials.gov) - Dec 17, 2015
P4, N=105, Enrolling by invitation, Sponsor: Sanofi Pasteur, a Sanofi Company
- Trial primary completion date: Infant Antibiotic Resistance and Implications for Therapeutic Decision-making (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=300, Recruiting, Sponsor: University Hospital Case Medical Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Dec 2016
- |||| Trial primary completion date: Combined Study - Phase 3b MenB Long Term Persistence in Adolescents (clinicaltrials.gov) - Dec 16, 2015
P3, N=650, Recruiting, Sponsor: Novartis Vaccines
Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: May 2016 --> Aug 2016
- Enrollment change: Rapid Detection of Group B Streptococcus (Strep)-Labor and Delivery Study (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of Michigan
Trial primary completion date: May 2016 --> Aug 2016 N=350 --> 0
- Review, Enrollment change, Trial withdrawal: Retrospective Review of Management of Infective Endocarditis (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=0, Withdrawn, Sponsor: Virginia Commonwealth University
N=350 --> 0 N=50 --> 0 | Active, not recruiting --> Withdrawn
- || gepotidacin (GSK2140944) / GSK
Trial primary completion date: A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae (clinicaltrials.gov) - Dec 14, 2015
P2, N=100, Recruiting, Sponsor: GlaxoSmithKline
N=50 --> 0 | Active, not recruiting --> Withdrawn Trial primary completion date: Oct 2015 --> Mar 2016
- Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
Enrollment closed, Trial primary completion date: Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. (clinicaltrials.gov) - Dec 14, 2015
P=N/A, N=1, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Oct 2015 --> Mar 2016 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Apr 2016
- Trial primary completion date: Simplified GBS Screening and Prevalence of ESBL in Pregnant Women (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=480, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Cubicin (daptomycin) / Merck (MSD)
Enrollment open, Trial primary completion date, Gram positive: Daptomycin in Pediatric Patients With Bacterial Meningitis (clinicaltrials.gov) - Dec 12, 2015
P1, N=5, Recruiting, Sponsor: University Hospital Inselspital, Berne
Trial primary completion date: Dec 2015 --> Dec 2016 Suspended --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2016
- Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
New trial: Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers (clinicaltrials.gov) - Dec 11, 2015
P=N/A, N=16, Completed, Sponsor: University of Oxford
- Enrollment change, Trial withdrawal: Tuberculosis Research Blood Bank (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=0, Withdrawn, Sponsor: New York University School of Medicine
Suspended --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2016 N=50 --> 0 | Active, not recruiting --> Withdrawn
- || ceftaroline fosamil / Generic mfg.
Trial primary completion date, HEOR: Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA (clinicaltrials.gov) - Dec 10, 2015
P4, N=166, Recruiting, Sponsor: Wayne State University
N=50 --> 0 | Active, not recruiting --> Withdrawn Trial primary completion date: Nov 2015 --> May 2016
- Biomarker, Trial completion: Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: iMACS Study (clinicaltrials.gov) - Dec 9, 2015
P=N/A, N=685, Completed, Sponsor: Columbia University
Trial primary completion date: Nov 2015 --> May 2016 Recruiting --> Completed
- Enrollment change: Evaluation of a Novel Midstream Urine Collection Technique for Infants in the Emergency Department (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=150, Recruiting, Sponsor: Children's Hospital of Eastern Ontario
Recruiting --> Completed N=50 --> 150
- || Altabax (retapamulin) / GSK, Almirall
Trial primary completion date: Retapamulin for Reducing MRSA Nasal Carriage (clinicaltrials.gov) - Dec 5, 2015
P4, N=150, Active, not recruiting, Sponsor: University of California, Irvine
N=50 --> 150 Trial primary completion date: Oct 2015 --> Aug 2016
- |||||||||| New P3 trial: Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen (clinicaltrials.gov) - Dec 5, 2015
P3, N=1080, Not yet recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- ceftriaxone / Generic mfg., azithromycin / Generic mfg.
Trial completion, IO biomarker: Chlamydia Trachomatis Immunology and Vaccinology Study (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=347, Completed, Sponsor: Harold Wiesenfeld
Trial primary completion date: Oct 2015 --> Aug 2016 Active, not recruiting --> Completed
- prednisone / Generic mfg.
Trial primary completion date: Pred-ART: Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone (clinicaltrials.gov) - Dec 5, 2015
P3, N=240, Recruiting, Sponsor: University of Cape Town
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Apr 2016
- azithromycin / Generic mfg.
Trial primary completion date: RESCUE-L: Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Jul 2016 --> Feb 2016
- Trial completion, Enrollment change, Trial primary completion date: Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=610, Completed, Sponsor: University of Milan
Trial primary completion date: Jul 2016 --> Feb 2016 Recruiting --> Completed | N=190 --> 610 | Trial primary completion date: May 2015 --> Oct 2015
- | Enrollment open: CAMERA2: Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection (clinicaltrials.gov) - Dec 4, 2015
P3, N=440, Recruiting, Sponsor: Menzies School of Health Research
Recruiting --> Completed | N=190 --> 610 | Trial primary completion date: May 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- rifampicin / Generic mfg.
Enrollment closed, Enrollment change: High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study (clinicaltrials.gov) - Dec 4, 2015
P2/3, N=32, Active, not recruiting, Sponsor: Universitas Padjadjaran
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=60 --> 32
- |||||| Enrollment open: Combined Study - Phase 3b MenB Long Term Persistence in Adolescents (clinicaltrials.gov) - Dec 4, 2015
P3, N=650, Recruiting, Sponsor: Novartis Vaccines
Recruiting --> Active, not recruiting | N=60 --> 32 Not yet recruiting --> Recruiting
- New trial: Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB (clinicaltrials.gov) - Dec 3, 2015
P=N/A, N=200, Recruiting, Sponsor: Chinese University of Hong Kong
- Enrollment closed: Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds (clinicaltrials.gov) - Nov 30, 2015
P=N/A, N=76, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial primary completion date: Iron Absorption and Utilization During Tuberculosis and After Treatment (clinicaltrials.gov) - Nov 30, 2015
P=N/A, N=18, Recruiting, Sponsor: Swiss Federal Institute of Technology
Recruiting --> Active, not recruiting Trial primary completion date: May 2016 --> Aug 2016
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment status, Pneumococcal vaccines: The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine (clinicaltrials.gov) - Nov 29, 2015
P4, N=162, Enrolling by invitation, Sponsor: Kameda Medical Center
Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Enrolling by invitation
- murepavadin (POL7080) / Spexis
Trial primary completion date: Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia (clinicaltrials.gov) - Nov 28, 2015
P2, N=25, Recruiting, Sponsor: Polyphor Ltd.
Recruiting --> Enrolling by invitation Trial primary completion date: Oct 2014 --> May 2016
- Enrollment change, Trial termination: Multi-center Evaluation of the VERSANT® CT/GC DNA 1.0 Assay (kPCR)in Detecting C. Trachomatis and N. Gonorrhoeae (clinicaltrials.gov) - Nov 28, 2015
P=N/A, N=2296, Terminated, Sponsor: Siemens Healthcare Diagnostics Inc
Trial primary completion date: Oct 2014 --> May 2016 N=3000 --> 2296 | Recruiting --> Terminated; Siemens Management decided not to release the product in the USA.
- New trial: HAP: Epidemiology of Hospital Acquired Pneumonia (clinicaltrials.gov) - Nov 26, 2015
P=N/A, N=214, Completed, Sponsor: University Hospital Olomouc
- Enrollment closed: SeTPAT: Treponema Pallidum-specific Proteomic Changes in Patients With Incident Syphilis Infection (clinicaltrials.gov) - Nov 26, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: Institute of Tropical Medicine, Belgium
N=3000 --> 2296 | Recruiting --> Terminated; Siemens Management decided not to release the product in the USA. Recruiting --> Active, not recruiting
- Trial completion: XACT: The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa (clinicaltrials.gov) - Nov 26, 2015
P=N/A, N=875, Completed, Sponsor: University of Cape Town
Recruiting --> Active, not recruiting Recruiting --> Completed
- rifampicin/isoniazid/ethambutol/pyrazinamide / Generic mfg.
Phase classification: Essentiality of INH in TB Therapy (clinicaltrials.gov) - Nov 25, 2015
P2, N=60, Recruiting, Sponsor: AIDS Clinical Trials Group
Recruiting --> Completed Phase classification: P2a --> P2
- Trial completion: Community-Onset Bacteremia Due to ESBL Producing E.Coli or K.Pneumoniae in China: Prevalence, Risk Factors and Prognosis (clinicaltrials.gov) - Nov 25, 2015
P=N/A, N=960, Completed, Sponsor: Jian-cang Zhou M.D.
Phase classification: P2a --> P2 Enrolling by invitation --> Completed
- | New P4 trial: Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study (clinicaltrials.gov) - Nov 24, 2015
P4, N=68, Completed, Sponsor: Baylor College of Medicine
- amikacin/fosfomycin inhalation (AFIS) / Savara
Enrollment change, Trial withdrawal, Gram positive, Gram negative: Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization (clinicaltrials.gov) - Nov 19, 2015
P2, N=0, Withdrawn, Sponsor: Cardeas Pharma
Enrolling by invitation --> Completed N=14 --> 0 | Active, not recruiting --> Withdrawn
- SQ-109 / Sequella
Enrollment change, Trial withdrawal: Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers (clinicaltrials.gov) - Nov 17, 2015
P2a, N=0, Withdrawn, Sponsor: Sequella, Inc.
N=14 --> 0 | Active, not recruiting --> Withdrawn N=30 --> 0 | Suspended --> Withdrawn
- Trial completion, Trial primary completion date: S1119 Peruvian H. Pylori Water Contamination Study (clinicaltrials.gov) - Nov 17, 2015
P=N/A, N=107, Completed, Sponsor: Southwest Oncology Group
N=30 --> 0 | Suspended --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Aug 2013
- || Trial primary completion date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - Nov 17, 2015
P=N/A, N=361, Recruiting, Sponsor: University of British Columbia
Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Aug 2013 Trial primary completion date: Dec 2015 --> Jun 2017
- |||| ribaxamase (SYN-004) / Synthetic Biologics
Enrollment open: A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI (clinicaltrials.gov) - Nov 17, 2015
P2, N=372, Recruiting, Sponsor: Synthetic Biologics Inc.
Trial primary completion date: Dec 2015 --> Jun 2017 Not yet recruiting --> Recruiting
- ||||| Zemdri (plazomicin) / Ionis, Achaogen
Enrollment change, Trial primary completion date: A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) (clinicaltrials.gov) - Nov 16, 2015
P3, N=480, Recruiting, Sponsor: Achaogen, Inc.
Not yet recruiting --> Recruiting N=360 --> 480 | Trial primary completion date: Jan 2017 --> Feb 2018
- |||||||||| Solithera (solithromycin) / Melinta Therap, Fujifilm Holdings
New P2/3 trial: Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia (clinicaltrials.gov) - Nov 16, 2015
P2/3, N=400, Not yet recruiting, Sponsor: Cempra Pharmaceuticals